Chemotherapy in Stage I/II NSCLC and projects of the EORTC-Lung Cancer Group for Early Stage Lung Cancer.
The utilization of systemic chemotherapy within multi-modality treatment concepts in early stage NSCLC would seem to be a very promising concept, which potentially could lead to increased survival rates. It must be noted, however, that application of multi-modality treatment strategies in Stage I and II NSCLC is still experimental and should only be applied within clinical trials. Caution is thus advisable because the existing data are not conclusive and there still are a great number of questions to be answered concerning at least: (1) the regimen, the intensity, the duration of therapy and the most appropriate schedule to be used for chemotherapy, (2) the most appropriate time for surgery and its extensiveness, and (3) the time, dose, and best application modus for radiotherapy. The Lung Cancer Group of the EORTC has been active in the clinical development of multi-modality treatment strategies to improve treatment results for patients with localized, early NSCLC and presently offers its members several attractive studies dealing with induction preoperative chemotherapy, induction preoperative chemo-radiotherapy, and sequential/concomitant chemo-radiotherapy.
Manegold
C
C
Thoraxklinik-Heidelberg gGmbH, Amalienstrasse 5, 69126 Heidelberg, Germany. prof.manegold@t-online.de
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005060:Europe; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015337:Multicenter Studies as Topic; D018714:Radiotherapy, Adjuvant; D012107:Research Design